Combined use of anticoagulant and antiplombocyte drugs in the treatment of COVID-19

COVID-19 is a severe and yet poorly understood infection that can affect almost all organs. The main target is the cells of the upper respiratory tract and alveolar tissue, which leads to the development of pneumonia and its complications. A decrease in these indicators is a poor prognostic sign. In addition, there may be an increase in ESR (erythrocyte sedimentation rate) and the number of platelets - cells that are responsible for blood clotting. Decreased platelet levels are less common.